R&D
1. Overseas licensing: leveraging overseas licensing as a cornerstone of developing innovative new drugs.
2. Drug delivery system development: focusing both on building in-house capacities and collaborating with DDS developers to develop incrementally modified new medicines.
3. Commercializing SAMA's advanced biotechnology: focusing on new bio product lineup and identifying a new engine for growth.
4. Effective sales growth: introducing products with competitive advantages to respond to both domestic and international market changes.
SAMA Pharmaceutical'sexperience and expertise has become the driving force for our innovative new medicine development efforts. We are also working on new drug candidate identification through outsourcing to and collaborating with external research institutions. The next step for SAMA is becoming a global player in drug research and development. To do that, we are strengthening our networks with domestic and overseas research institutions and building core research capabilities.
The goal of new medicines developing innovative new drugs that can be a global blockbuster
And ultimately, it is to help people live a healthier and happier life. SAMA's research and development efforts are devoted mostly to major therapeutic areas nad diseases as part of our 'choice and focus' strategy. Also, SAMA is working with various partners to introduce world-class and innovative new medicines.
Efficiency Oriented :To fast identify outstanding new drug candidates
Market Oriented : To develop innovative medicines in great social demand
Innovation Oriented : To become a leader in identifying new molecules
Originality Oriented : To obtain globally competitive new medicines
With the application of the drug delivery system [DDS] to the existing medicines,SAMA has focused on developing improved medicines that aim to enhance the effectiveness of medicines and patient compliance based on its accumulated know-how in the area of new formulation, SAMA has developed a dispersible tablet.
Furthermore, SAMA is working on developing new technologies that can be used in reducing dosing frequency and improving bioavailability.
SAMA will introduce medicines that are different, upon considering the usage, formulation, package, administration, and safety improvement of these certain medicines.
We are developing next generation versions of our existing products and exploring the feasibility of current products in new indications as well as new delivery routes We continue to strengthen internal R&D capabilities and establish R&D collaboration with various pharmaceutical and drug delivery system companies